NASDAQ:KRTX
Delisted

Karuna Therapeutics Stock News

etoro logo Buy KRTX
*Your capital is at risk
$329.83
+0 (+0%)
At Close: Jun 14, 2024
Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.

Biotech Melt-Up

01:00pm, Thursday, 23'rd Apr 2020
A high daily death toll suggests a much more careful and measured reopening of the economy will be possible, not a quick-paced one. The pandemic thrusts the bio
As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).

Stock Market's Next Move

07:00pm, Thursday, 09'th Apr 2020
The market remains unsettled but is moving higher as it expects good things to happen after the hot spots peak. The impact of the pandemic will keep expanding d
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Raymond James & Associates bought a new position in shares of Karuna Therapeutics (NASDAQ:KRTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities a
Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Apellis Pharmaceuticals (NASDAQ:APLS) initiated with an Outperform rating and a $54 (88% upside) price target at BMO.Arena Pharmaceuticals (NASDAQ:ARNA) initiated with a Buy rating and a $95 (126% ups

Reviving A Comatose Economy

03:34pm, Thursday, 26'th Mar 2020
A deliberate slowing down of the economy is in progress in order to preserve it. The key question remains how soon can we start recovering. The expected $2 tril
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote
Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Karuna Therapeutics (KRTX) today and set a price target of $120.00. The company's shares
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE